In This Section

The NLRP3 Inflammasome as a Pharmacological Target in Cardiovascular Disease

Saturday April 04, 2020

11:00 am - 1:00 pm Eastern Time (ET)

Room 15 B


Chair :

Joan Heller Brown
University of California, San Diego

Shigeki Miyamoto
University of California, San Diego

The NLRP3 inflammasome senses various intracellular and extracellular stress signals and orchestrates inflammation through production of IL-1β and IL-18. A significant role for NLRP3 inflammasome signaling in cardiovascular aging, atherosclerosis and heart failure has recently been revealed. Remarkably, clinical trials using canakinumab, an IL-1β antibody and anakinra an IL-1 receptor blocker indicate that inhibition of the inflammasome could be effective in the treatment of various aspects of cardiovascular disease. This symposium will discuss recent progress in our understanding of molecular signals regulating the NLRP3 inflammasome and evidence that the NLRP3 inflammasome is a critical new therapeutic targets for cardiovascular disease.


Stefano Toldo - VCU Pauley Heart Center, Virginia Commonwealth University

NLRP3 Inflammasome Inhibition in Acute Myocardial Infarction and Heart Failure

Na Li - Baylor College of Medicine

Inflammasome and Atrial Fibrillation

Kenneth Walsh - University of Virginia School of Medicine

Somatic Mutations, Clonal Hematopoiesis and NLRP3 Inflammasome Activation in Cardiovascular Disease

John Shyy - University of California, San Diego

NLRP3 Inflammasome in Endothelial Dysfunction

Shigeki Miyamoto - University of California, San Diego

NLRP3 Inflammasome Activation in Cardiomyocyte Mediated Inflammation

Erik Hett - Merck & Co., Inc.

The Therapeutic Potential of Targeting the NLRP3 Inflammasome

Last Updated: December 10, 2020
Key Dates
March 6

Housing discounts end

March 13

Advance Registration Ends

April 3-4

GPCR Colloquium (separate ticket required)

April 4

ASPET Business Meeting and Awards Presentation

April 4-7

ASPET Annual Meeting at EB 2020

Thank you to our Annual Meeting partners:

University of Kentucky
Icahn School
University of Georgia
University of Minnesota
WSU Pharm-Pharm Sciences Unit
PR & P